Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21453980 | 0.96 | ALDH1A1 (0.36) | ALDH1A1TSHRCYP2C19ACHEKDM4E | |
| SCHEMBL21453908 | 0.91 | DDB1 (0.36) | ALDH1A1TSHRCYP2C19ACHE | |
| SCHEMBL22139297 | 0.90 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP2C19ACHEKDM4E | |
| SCHEMBL21454339 | 0.90 | PDE4B (0.32) | ALDH1A1TSHRCYP2C19ACHE | |
| SCHEMBL804802 | 0.89 | ALDH1A1 (0.37) | ALDH1A1TSHRCYP2C19ACHEKDM4E | |
| SCHEMBL13172892 | 0.89 | ALDH1A1 (0.34) | ALDH1A1TSHRCYP2C19ACHEKDM4E | |
| SCHEMBL13172890 | 0.89 | ALDH1A1 (0.34) | ALDH1A1TSHRCYP2C19ACHEKDM4E | |
| SCHEMBL24676250 | 0.89 | L3MBTL1 (0.42) | ALDH1A1KDM4EATML3MBTL1GPR3 | |
| SCHEMBL16743110 | 0.89 | L3MBTL1 (0.42) | ALDH1A1KDM4EATML3MBTL1GPR3 | |
| SCHEMBL21453455 | 0.88 | KDM4E (0.34) | ALDH1A1ACHEKDM4EATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11469381-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-10-11 | — | — | US | disclosed |
| US-20190312209-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11469381-B2 | Condensed cyclic compound and organic light-emitting device including the same | ARL1, CCNL2, CRY1 | ALDH1A1 312/4885TSHR 3537/4885CYP2C19 2096/4885 |
| US-20190312209-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | ARL1, CCNL2, CRY1 | ALDH1A1 312/4885TSHR 3537/4885CYP2C19 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.